1. González-López E, Gallego-Delgado M, Guzzo-Merello G, Moral FJH-D, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585-94.
2. Simões MV, Fernandes F, Marcondes-Braga FG, Scheinberg P, Correia EB, Rohde LEP, et al. Posicionamento sobre diagnóstico e tratamento da amiloidose cardíaca – 2021. Arq Bras Cardiol. 2021; 117(3):561-598.
3. Rassi S, Rassi DC, Freitas Junior AF. Qual a Importância das pistas clínicas, como não errar em segui-las? ABC Heart Fail Cardiomyop. 2021; 1(2):124-126.
4. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007-16.
5. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138(9):861-70.
6. Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22(3):391-412.
7. Pauta da 129ª Reunião Ordinária CONITEC. Disponível em: https://www.gov.br/conitec/pt-br/midias/reuniao_conitec/2024/Pautada129ReunioComitedeMedicamentos.pdf. Acesso em: 24 out. 2024.
8. Lockwood PA, Le VH, O’Gorman MT, Patterson TA, Sultan MB, Tankisheva E, et al. The Bioequivalence of Tafamidis 61-mg Free Acid Capsules anda Tafamidis Meglumine 4 x 20-mg Capsules in Healthy Volunteers. Clin Pharmacol Drug Dev 2020;9(7):849-54.
Exclusividade médica
